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Abstract Next generation sequencing (NGS) technology,
with the ability to sequence many genomic regions at once,
can provide clinicians with increased information, in the form
of more mutations detected. Discussions on broad testing
technology have largely been focused on incidental findings,
or unanticipated results related to diseases beyond the primary
indication for testing. By examining multiple genes that could
be responsible for the patient’s presentation, however, there is
also the possibility of unexpected results that are related to the
reason genetic testing was ordered. We present a case study
where multiple potentially causative mutations were detected
using NGS technology. This case raises questions of scientific
uncertainty, and has important implications for medical man-
agement and secondary studies. Clinicians and genetic coun-
selors should be aware of the potential for increased informa-
tion to affect one’s understanding of genetic risk, and the pre-
and post-testing counseling process.
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Introduction
Next generation sequencing (NGS) is expanding clinicians’
ability to search for and identify causative mutations for
genetic diseases. These sequencing technologies allow for
the simultaneous sequencing of large numbers of genomic
regions, and so genetic testing strategies are expanding from
examining a single gene, to a panel of genes, to the whole
exome, and finally, the whole genome. The wealth of genetic
information that can be produced from this technology pre-
sents new dilemmas and poses additional risks when NGS is
applied in a clinical diagnostic setting.
Much of the discussion surrounding NGS has focused on
the implications of secondary, or incidental, findings, defined
as genetic variants that are known or suspected to be patho-
genic, but that confer risk of diseases unrelated to the reason
that genetic testing was ordered (Raffan and Semple 2011).
These are genetic results that neither the clinician nor the
patient anticipated when the test was ordered (Wolf et al.
2008). However, next generation sequencing also has the
possibility to provide unanticipated results that are highly
relevant to the patient’s clinical diagnosis.
With NGS, multiple genes are sequenced at once, which can
result in the identification of pathogenic mutations in more than
one gene. Prior to NGS, finding a potentially pathogenic mu-
tation in one gene may have ended the search for a molecular
diagnosis. We are reporting here a case where potentially caus-
ative variants were detected in two different genes, where
mutations in a single gene could be considered sufficient to
cause the condition. This case raises questions of scientific
uncertainty and has implications for risk counseling. We
wanted to bring this case to attention because, as NGS becomes
more widely utilized, genetic counseling must adapt to new
technologies that generate a broader set of potential etiologies.
Case Study
A 6 year-old male presented to our Retinal Dystrophy Clinic
complaining of a rapid decline in his vision in the past year. He
reported that he could not see the stars at night, could no
longer see the board at school, needed to increase font size
for reading, and had a loss of color vision. At his visit, his
visual acuity, as measured against a Snellen Chart, was mea-
sured as 20/200 in the right eye and 20/150 in the left eye,
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where 20/20 is considered normal visual acuity. A Goldmann
Visual Field measurement demonstrated constricted visual
fields with a large central scotoma, or blind spot. Color vision
testing, using both Ishihara plates and Farnsworth testing, was
abnormal. The results of his electroretinogram, which mea-
sures the electrical response from the cone and rod photore-
ceptor cells in the retina, showed a normal cone response but a
reduced rod response.
His family history (Fig. 1) was significant for a paternal
uncle who was clinically diagnosed with a cone-rod dystrophy
around age 7, and had a similar presentation to our patient:
reduced visual acuity and large central scotomas in both eyes.
An electroretinogram performed at age 32 showed a non-
recordable cone response and a reduced rod response. Paternal
ancestry is Korean and maternal ancestry is Taiwanese. There
was no reported history of consanguinity.
Based on the patient’s symptoms, clinical testing, and
family history, he was diagnosed with a cone-rod
dystrophy.The family was counseled about both autoso-
mal dominant inheritance with reduced penetrance and
autosomal recessive inheritance. Clinical genetic testing
was ordered for a panel of 25 genes associated with
cone-rod dystrophies inherited in an autosomal reces-
sive, autosomal dominant, or X-linked manner (Table 1).
Although this panel contains identified genes associated
with cone-rod dystrophies, not all genes associated with
cone-rod dystrophies are known at this time (Hamel
2007).
Genetic Testing Results
Genetic testing identified three novel variants in two different
genes that could potentially provide an explanation for the
patient’s phenotype. Two variants, IVS23-2A>T and
c.2249T>C, were found in the ABCA4 gene and one variant,
c.1282C>G, was found in the RPGR gene.
The ABCA4 gene is located on chromosome 1 and pro-
duces an ATP-binding cassette transmembrane protein that is
involved in the retinoid visual cycle. Mutations in ABCA4 are
associated with several different autosomal recessive
retinal dystrophies, including Stargardt disease, retinitis
pigmentosa, and cone-rod dystrophy (McKusick and
O’Neill 2011). Novel variants in this gene are not
uncommon, as over 600 different variants in ABCA4
have been identified to date (Allikmets 2007).
RPGR is located on the X chromosome, is expressed in the
outer segments and connecting cilia of cone and rod photore-
ceptor cells, and is essential for photoreceptor maintenance.
Mutations in RPGR are associated with X-linked retinal dys-
trophies, including cone-rod dystrophy and retinitis
pigmentosa (McKusick and Kelly 2013).
Interpreting Novel Variants of Uncertain Significance
To interpret novel variants of uncertain significance, one uses
multiple lines of evidence to determine if a variant is associ-
ated with disease. Direct lines of inquiry include co-
segregation analyses and case–control studies and indirect
evidence includes in vitro assays or bioinformatics modeling.
We routinely obtain parental samples for segregation anal-
ysis in our clinic. From an analysis of parental samples, the
clinical laboratory determined that the ABCA4 variant IVS23-
2A>G was maternally inherited, and that the ABCA4 variant
c.2249T>C was paternally inherited. The RPGR c.1282C>G
variant was determined to be maternally inherited, and not de
novo in our patient.
To determine if the paternally inherited variant is segregat-
ing with disease, we recommended that the patient’s paternal
uncle be tested for mutations in the ABCA4 gene. It is possible
that he possesses two mutations in ABCA4 - the same variant
that our patient inherited from his father, and a different
mutation. Determining if ABCA4 mutations are responsible
for the uncle’s similar presentation may provide additional
evidence for the pathogenicity of the paternal ABCA4 allele.
None of the variants have been previously reported in the
literature or any of the databases that were searched. A differ-
ent variant at the same position as the maternally inherited
variant, IVS23-2A>T, was reported in three siblings with
autosomal recessive retinitis pigmentosa, all of whom had a
previously reported mutation on the opposite allele (Mandal
et al. 2005). In this report, the variant was detected in a
heterozygous state in the mother and in another unaffected
sibling, and was not detected in another unaffected sibling.
Using in silico analysis the authors predicted IVS23-2A>T
caused the loss of a splice acceptor site.
A bioinformatics approach uses in silico analysis to con-
sider evolutionary conservation, the predicted severity of an
amino acid substitution, and the predicted effects of exonic or
intronic alterations on protein splicing. The maternally
inherited variant IVS23-2A>G was predicted to affect a splice
site, and was predicted to be damaging by NetGEN2, a web-
based splice-site prediction software package. The paternally
inherited variant c.2249T>C was predicted to be “probably
damaging” using in silico analysis programs Polyphen-2,
SIFT, andMutation Taster. Conservation modules inMutation
Taster also suggested that this was a highly conserved amino
acid residue. In silico analysis of the RPGR variant
c.1282C>G provided contradictory, and therefore uninforma-
tive, results, as it was predicted to be damaging by Polyphen-2
and SIFT, but predicted to be a benign polymorphism by
Mutation Taster. In silico models are not definitive. Some
variants now recognized as pathogenic were initially predicted
to be benign, and some variants that were initially predicted
to be damaging have later been reclassified as non-
pathogenic. Furthermore, these programs are not
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designed for clinical use and do not provide sufficient
evidence for clinical decision-making.
Family Post-Test Counseling
The patient and his family received counseling about the
potential implications of the ABCA4 and RPGR variants.
The family was counseled that the ABCA4 variants might
provide a genetic explanation for his loss of vision, and
autosomal recessive inheritance was again reviewed. We also
discussed X-linked inheritance for the RPGR variant. Since it
has been reported that RPGR carrier females can exhibit a
range of symptoms, ranging from asymptomatic to retinal
disease comparable to males, we recommended that the pa-
tient’s mother have an electroretinogram and color vision
testing performed, have her visual acuity and visual fields
measured, and have fundus photographs taken (Churchill
et al. 2013). Additional genetic testing for mutations in
ABCA4 for patient’s paternal uncle was recommended, be-
cause without knowing the uncle’s genotype, our ability to
interpret our patient’s genotype is limited.
Discussion
We present this case to highlight that challenges in providing a
molecular diagnosis in the age of NGS panels are not only
related to incidental findings, but testing may also identify
several possible causes for disease. The detection of multiple
potential explanations for disease raises questions of uncer-
tainty regarding whether or not any of the variants contribute
to the phenotype, and if so, the extent of their contribution.
Finding variants of unknown significance underscores the
underlying complexity of Mendelian conditions, creates the
need for additional studies or analyses to clarify testing results,
and raises questions about how this type of information needs
to be communicated to patients. Many of these issues are not
new to the genetic counseling field, but they are important to
Fig. 1 Our patient is indicated by the arrow (IV-2). The patient’s paternal uncle was also diagnosed with a cone-rod dystrophy (Individual III-1)
Table 1 Testing was performed for these 25 genes using next generation
sequencing
Gene Inheritance mode
AIPL1, c8ORF37, CRX, GUCA1A,
GUCY2Da, PITPNM3, PROM1,
PRPH2/RDS, RAX2, RIMS1,
SEMA4A, UNC119
Autosomal dominant
ABCA4, ADAM9, CACNA2D4,
CDHR1, CERKL, CNGB3, CNNM4,
GUCY2Da, KCNV2, PDE6C, RDH5,
RPGRIP1
Autosomal recessive
CACNA1F, RPGR X-linked recessive
Sanger sequencing was performed to fill in gaps and low coverage
regions. Novel variations were confirmed with Sanger sequencing
aMutations in GUCY2D have been reported in families exhibiting both
autosomal dominant and autosomal recessive modes of inheritance
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discuss because they will likely become more common as
broader testing is performed for more patients.
Uncertainty
Interpreting how even a single variant might influence the
onset or progression of disease remains difficult. Any genetic
variant needs to be carefully evaluated in the context of the
family history. Our patient’s family history was most consis-
tent with autosomal dominant inheritance with incomplete
penetrance. Cone-rod dystrophy is a rare condition, and would
generally not be expected to occur in an autosomal recessive
pattern of inheritance in multiple generations of a family
without consanguinity. Furthermore, there is a single report
in the literature of the pseudodominant inheritance of
Stargardt disease in a family with an ABCA4 variant (Shroyer
2000). The identification of variants in genes associated with
autosomal recessive or X-linked inheritance, and negative
genetic testing results with regards to known mutations in
known genes associated with autosomal dominant cone-rod
dystrophies, needs to be considered cautiously.
The detection of multiple genetic variants adds to the
uncertainty regarding the contribution of each one to disease.
Since each patient represents a unique case, and there have
been no other reports in the literature of patients with both
ABCA4 and RPGR mutations, it is unclear if the variant(s) in a
single gene provide an explanation for the patient’s vision
loss, or if the effects of multiple variants are additive. In
familial cases, more than one mutation may co-segregate with
disease, making it difficult to parse out the effects of each
mutation (Raffan and Semple 2011). There are also rare re-
ports of digenic inheritance for retinitis pigmentosa (Kajiwara
et al. 1994) and Bardet-Biedl syndrome (Fauser et al. 2003). In
digenic inheritance, mutations in multiple genes each contrib-
ute to disease, and each mutation by itself is thought to be
insufficient to explain the condition. This is distinct from the
case we present, where variants in a single gene, either
ABCA4 or RPGR , could independently provide an explana-
tion for our patient’s phenotype.
There are additional challenges for how these types of
results may impact medical management. Clinical trials for
gene therapy for individuals with Stargardt disease who have
molecular confirmation of ABCA4 mutations are underway
(www.clinicaltrials.gov). If at least one of the variants found in
our patient can be classified as pathogenic, he might qualify to
participate in a future clinical trial. But might the presence of
an RPGR variant be considered a “concurrent disease” or
“laboratory abnormality” that would exclude him from
such a trial? It is also unknown how the presence of
an RPGR variant might affect his response to gene
therapy for a different gene.
These testing results also have implications for treatment
recommendations. Dietary supplementation with vitamin A is
sometimes prescribed for individuals with retinal dystrophies.
VitaminA supplementation should be avoided in patients with
ABCA4 mutations, however, due to the accumulation of toxic
pigments in the eye (Radu et al. 2008). At the patient’s initial
visit, the physician discussed vitamin supplementation with
the family. Subsequent to genetic testing, Vitamin A supple-
mentation was not recommended.
Despite increasing the complexity of a management strat-
egy for the patient, NGS provided important information to
the clinician that single gene testing may have missed. If,
based on the family history, the most likely mode of inheri-
tance was believed to be autosomal dominant inheritance with
reduced penetrance, and the patient had only had testing for
the RDS gene, for example, it would not have been known
that Vitamin Awas contraindicated. This case highlights how
NGS technology can be useful in an era of personalized
medicine, where healthcare is customized based on the pa-
tient’s genetic information.
The experience with genetic forms of cardiovascular dis-
orders provides some insight into how one might utilize and
make sense of the increased volume of information on each
patient, as panel-based testing has been available for a number
of years. In the literature, there are many patients with cardio-
myopathies who have multiple disease-causing mutations
(Alpert et al. 2005). Because there have been enough cases,
studies suggest that having multiple mutations increases an
individual’s risk to develop end-state disease or experience
sudden cardiac death (Girolami et al. 2010). In the cardiovas-
cular field, patients can now be offered more accurate infor-
mation about their risk of complications. As more patients
with retinal dystrophies receive panel-based testing or whole
exome testing, it may be possible to establish a large enough
patient base to determine howmuch eachmutation contributes
to a patient’s phenotype.
NGS provides the opportunity to peel back the curtain, to
reveal more details about the genetic background of a patient
that were previously unseen. The case described above can
serve as a reminder that mutations do not exist in a vacuum,
but they occur within the context of the patient’s entire genome.
There are many genes involved in the visual cycle, for example,
and variations in each one may play a role in how a patient
experiences vision loss. While Mendelian conditions have tra-
ditionally been thought of as “one gene, one condition”, there
are many studies that demonstrate that genetic variants modify
disease expression (e.g., Fahim et al. 2011). When one intro-
duces the idea of genetic modifiers, it becomes harder to
confidently link a disease to mutations in only one gene.
As more data become available on each newly discovered
genetic variant, variants will continue to be reevaluated and
reclassified. Researchers and clinicians will also learn more
about the interactions between genes and mutations. In the
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future, having a more complete picture of an individual’s
genotype may provide an explanation for some of the vari-
ability that is seen in some genetic conditions. Clinicians will
continue to struggle with how to translate these findings into
meaningful information for patients, however, until they have
much more data and better tools to able to understand richer
genetic information.
Secondary Studies
Our case example also illustrates that the degree to which
additional analyses may need to be performed will likely
increase with the use of NGS. For our patient, we requested
parental samples to provide confirmation of the segregation
pattern of the ABCA4 and RPGR variants. Additional testing,
such as whole exome sequencing (WES), which might iden-
tify additional variants in our patient and his paternal uncle
that would explain the cone-rod dystrophy, should also be
considered. Given that there is an affected individual outside
the patient’s nuclear family, a more traditional type of
genetic investigation, in the form of linkage analysis,
may also be possible.
The ambiguity resulting from a lack of functional studies of
the effect of these variants demonstrates the burden on the
clinician for the diagnostic dilemma presented by a novel
variant. Functional testing of the effects of each variant could
also be conducted. Laboratory or animal studies of the bio-
logical effect of the variant may provide evidence that it is
causative. These types of studies provide indirect evidence to
clarify whether a variant is benign or pathogenic.
Communicating Information to Patients
Using NGS technology increased the amount of information
that we needed to provide to our patient to explain the results,
and raised some additional questions about the type and
amount of information that needs to be provided in
pre-test counseling.
While returning the genetic testing results to our patient, we
discussed additional modes of inheritance that were not ini-
tially suggested based on the pedigree. We initially discussed
autosomal dominant inheritance with reduced penetrance.
After genetic testing, we discussed both autosomal recessive
and X-linked inheritance in more depth. Since we
discussed multiple modes of inheritance, we discussed
several different risk estimates.
Even in cases where mutations in multiple genes have the
same mode of inheritance, the discussion of risk becomes
more complex. For an individual with a BRCA1 mutation,
the risk to his or her children of inheriting the mutation is
50 %. For an individual with both a BRCA1 and a BRCA2
mutation, the risk to his or her children of inheriting at least
one mutation is 75 %. Individuals who have both BRCA1 and
BRCA2 mutations (Musolino et al. 2005; Steffensen et al.
2010), or both APC and MSH2 mutations (Uhrhammer and
Bignon 2008), have been reported in the literature.
For our patient, we ordered panel-based testing that inves-
tigated genes associated with conditions with autosomal re-
cessive, autosomal dominant, and X-linked inheritance. Based
on the results that were obtained, however, should pre-test
counseling have included an in-depth discussion of all three
modes of inheritance? Our practice model already includes a
discussion of multiple modes of inheritance for simplex cases
of retinitis pigmentosa, because one study showed that 15 %
of males with no family history of retinitis pigmentosa had a
mutation in a gene associated with X-linked retinitis
pigmentosa (Branham et al. 2012) and a separate study
showed that 10 % of individuals with no family history
of retinitis pigmentosa had a mutation in a gene asso-
ciated with autosomal dominant retinitis pigmentosa
(Neveling et al. 2012).
NGS technologies have also raised questions about what
needs to be included in the informed consent process, specif-
ically regarding the possibility of incidental findings. Coun-
selors report that this has allowed them to discuss with patients
which type of information they would like to receive, but this
has also considerably lengthened the informed consent pro-
cess (Raffan and Semple 2011). In general, in the informed
consent process for genetic testing, the clinician may discuss
the possibility of positive results (finding a genetic explana-
tion for disease), negative results (not detecting a mutation), or
the possibility of finding a variant of unknown significance. If
there is also the potential for what amounts to multiple results,
should that also be included in the discussion?
Practice Implications and Conclusions
We present this case because the ability to offer more complex
genetic diagnostic testing has implications for how to think
about what it means to provide comprehensive genetic
counseling to patients. Panel-based testing is currently avail-
able for a number of conditions, such as cardiomyopathies,
retinal dystrophies, and aneurysmal disorders, among others.
Due to advances in whole exome and whole genome testing,
we may see this scenario even for conditions where panels are
not currently established.
Based on our experience in this case, we would stress the
importance of clinical support services that help individuals
make sense of the entire genetic testing process. Pre-test
counseling should include a discussion of the potential bene-
fits and risks of testing, the limitations of testing, the potential
for unanticipated or ambiguous results, and that additional
testing may be needed to clarify results. If relevant to the
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NGS panel, patients should be made aware that testing con-
siders genes associated with conditions with different patterns
of inheritance. Post-test counseling should be a discussion of
the results, including what is known and unknown about
potentially causative variants. Patients may also be encour-
aged to re-contact the clinic to determine if variants have been
reclassified, or to discuss additional testing.
This case is brought to attention so that clinicians and
genetic counselors can refine their understanding of genetic
risk in light of increased information. Patients may then be
counseled about the potential of NGS technology to detect
more information about their condition, and understand how
this information will be used in their medical care.
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